Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » Jubilant Biosys Limited

Jubilant Biosys Limited

Table of Contents
Table of Contents

Jubilant Biosys Limited is a Contract Research and Manufacturing Organization (CRMO) that provides integrated services from early drug discovery to preclinical studies for global pharmaceutical and biopharmaceutical companies. With bases in India and Europe, we contribute to the creation of innovative therapeutics through high-quality research and development support.

Here, we will introduce in detail Jubilant Biosys Limited strengths in non-clinical studies, examples of disease models they possess, and specific use cases.

Jubilant Biosys Limited' Contract Non-Clinical Testing Services Features

Addressing a wide range of disease areas

One of Jubilant Biosys Limited's features is its ability to address a wide range of disease areas, including cancer, central nervous system disorders, metabolic diseases, pain, and inflammation. At its advanced research facilities in India and France,in vitroandin vivoWe offer a wide range of non-clinical testing services, from pharmacology studies to drug metabolism and pharmacokinetics (DMPK) studies, and GLP and non-GLP toxicology studies, flexibly meeting the diverse drug discovery needs of our customers.

An integrated approach with comprehensive facilities

Another key feature is our integrated approach, leveraging comprehensive facilities and advanced expertise. Our experienced team of scientists utilize high-performance infrastructure to deliver high-quality data, supporting rapid decision-making from the early stages of development. We go beyond simple contract testing; as a CRDMO, we offer end-to-end support, from identifying drug discovery targets to preclinical testing and even the scale-up manufacturing of active pharmaceutical ingredients, thereby facilitating a more efficient drug discovery process.

An example of a pathological model held byJubilant Biosys Limited

Diversein vivoPathological model

The company offers a wide range of [products/services] to thoroughly evaluate complex disease mechanisms.in vivoI own animal models.

Representative examples include pain models that evaluate chemotherapy-induced allodynia and bone cancer pain, and skin disease models for contact dermatitis and psoriasis. In addition, "metabolic disease models," including diabetes, are well-developed, supporting the efficacy evaluation of new drug candidate compounds with study designs tailored to the characteristics of each disease.

Reference: Jubilant Biosys Limited Official Website
https://www.jubilantbiosys.com/services/in-vivo-pharmacology/

Advanced oncology models

For cancer, a key focus area, we offer a rich selection of proprietary, advanced oncology models. Specifically, evaluation systems utilizing a wide variety of cancer cell lines, including pancreatic, lung, and breast cancer, are available. By leveraging these models, which are based on past research trends, we can meticulously validate the efficacy and mechanisms of action of anticancer drugs, thereby supporting efforts to accelerate and achieve success in the development of innovative pharmaceuticals in the field of oncology.

Reference: Jubilant Biosys Limited Official Website
https://www.jubilantbiosys.com/integrated-drug-discovery-services/

Jubilant Biosys Limited's Non-Clinical Study Cases

Due to the nature of being a CRDMO, strict confidentiality agreements (NDAs) are in place, and details of individual drug discovery program support are not publicly disclosed on our website. For approaches to specific disease targets or detailed case studies, please contact us directly to receive information disclosure or proposals tailored to your requirements.

Jubilant Biosys Limited also supports the non-clinical studies of its sister company, Jubilant Therapeutics. The following are case studies featured in Jubilant Therapeutics' public disclosures.

New anti-cancer drug non-clinical study cases

We conducted non-clinical studies on "JBI-778," a novel PRMT5 inhibitor candidate for anti-cancer drugs. This compound isin vitroIn addition to demonstrating antitumor activity in preclinical studies, oral administration achieved greater than 90% tumor growth inhibition in a mouse Z-138 xenograft model%.

Furthermore, sustained exposure and substantial survival extension in the brain have been confirmed in a glioblastoma (GBM) model of the same location, showing promising data as a clinical candidate.

Jubilant Biosys Limited Company Information

Jubilant Biosys Limited is a global company that seamlessly supports early drug discovery research through to commercial production. Leveraging its infrastructure and expertise, it holistically supports its customers' drug development.

Address India (Bengaluru, Noida, Greater Noida), France (Saint-Julien-en-Genevois)
Tel +91 120 436 1000 (Representative of Head Office in India)
Website https://www.jubilantbiosys.com/

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services